BioMarin Pharmaceutical vs Neurocrine Biosciences
BMRN and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and NBIX compare
Neurocrine Biosciences is the larger company, worth 1.3 times as much as BioMarin Pharmaceutical ($14.9B against $11.3B).
On earnings, Neurocrine Biosciences is cheaper: it trades at 21.4× trailing earnings, against 154× for BioMarin Pharmaceutical.
Neurocrine Biosciences grew revenue faster over the last twelve months (34.4% versus 11.2% for BioMarin Pharmaceutical).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with 2.1% at BioMarin Pharmaceutical.
Neurocrine Biosciences scores higher on the StockData Score (19 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $11.3B | $14.9B |
| Share price | $58.51 | $146.10 |
| Change, 1 year | 12.8% | 5.9% |
| Change, 5 years | −30.3% | 56.7% |
| Beta (5Y) | 0.59 | 0.49 |
| Employees | 3,221 | 1,800 |
| StockData Score | ||
| Total score | 8 | 19 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 154× | 21.4× (better) |
| P/S | 3.3× (better) | 4.4× |
| P/B | 1.8× (better) | 4.0× |
| EV/EBITDA | 48.4× | 18.2× (better) |
| P/FCF | 15.3× (better) | 17.1× |
| PEG | 4.54 | 0.49 (better) |
| FCF yield | 6.5% (better) | 5.9% |
| Fair value | $23.86 | $177.51 |
| Margin of safety | −145% | 17.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% | 34.4% (better) |
| Revenue growth, 5Y average | 11.6% | 22.3% (better) |
| Net income growth (TTM) | −88.9% | 103% (better) |
| EPS growth (TTM) | −88.7% | 102% (better) |
| EPS growth, 5Y average | −16.7% | 2.3% (better) |
| Profitability | ||
| Gross margin | 76.1% | 98.0% (better) |
| Operating margin | 4.4% | 23.6% (better) |
| Net margin | 2.1% | 20.9% (better) |
| FCF margin | 21.7% | 25.8% (better) |
| Return on equity | 1.2% | 22.1% (better) |
| Return on invested capital | 1.0% | 23.7% (better) |
| Financial health | ||
| Debt / equity | 0.66 (better) | 0.00 |
| Net debt / EBITDA | 10.96 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.39 (better) | 1.87 |
| Altman Z-score | 1.86 | 6.83 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.84% |
| Shareholder yield | 0.00% (better) | −0.84% |
| Ownership | ||
| Held by institutions | 101% | 99.5% |
| Held by insiders | 0.53% | 1.2% |
| Insider net buying, 12 months | −$4.3M (better) | −$77.9M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.0% | 5.8% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.